OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TAKE57

Take Solutions Ltd

Biotechnology & Medical ResearchVerified

Take Solutions operates with a strong equity base, as evidenced by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company maintains a current ratio of 1.48, suggesting it has sufficient short-term assets to cover its liabilities. However, the operating cash flow of -164.49 million INR indicates a cash outflow from operations, which could be a concern for liquidity. The free cash flow of 7.44 million INR is positive but relatively small, suggesting limited flexibility for reinvestment or shareholder returns. The company's profitability is highlighted by a return on equity (ROE) of 1.8253 and a return on assets (ROA) of 1.0271, both of which are strong indicators of efficient use of equity and assets. These metrics suggest that Take Solutions is generating solid returns for its shareholders and effectively utilizing its asset base. Take Solutions' revenue is not disclosed in the latest financial snapshot, but the company's global client base includes large and small biopharmaceutical and device companies, as well as U.S. federal agencies like the CDC and the DoD. This diverse client portfolio may help mitigate geographic and sector-specific risks. The company's growth trajectory is not clearly defined in the latest financial data, as revenue is reported as 0.0 INR. However, the positive net income of 374.67 million INR suggests that the company is profitable. The absence of capital expenditure and the presence of a small free cash flow indicate that the company may be in a maintenance phase rather than an expansion phase. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's strong equity position and lack of long-term debt contribute to its low liquidity risk. The dilution risk is also low, suggesting that the company is not expected to issue additional shares in the near term. Recent events and filings do not show any significant changes in the company's financial or operational status. The company's financial snapshot does not include any recent events or transcripts, but the absence of negative flags suggests that the company is operating within normal parameters.

30-day price · TAKE-14.81 (-36.6%)
Low$25.60High$50.14Close$25.60As of17 May, 00:00 UTC
Profile
CompanyTake Solutions Ltd
TickerTAKE.NS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Take Solutions Limited provides contract research organization (CRO) services to pharmaceutical, biotech, and medical device companies, offering clinical research, data sciences, and regulatory affairs services, with clients including the CDC and U.S. Department of Defense.

Classification. Take Solutions is classified under the Healthcare sector, specifically in the Biotechnology & Medical Research industry, with a confidence level of 0.92.

Take Solutions operates with a strong equity base, as evidenced by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company maintains a current ratio of 1.48, suggesting it has sufficient short-term assets to cover its liabilities. However, the operating cash flow of -164.49 million INR indicates a cash outflow from operations, which could be a concern for liquidity. The free cash flow of 7.44 million INR is positive but relatively small, suggesting limited flexibility for reinvestment or shareholder returns. The company's profitability is highlighted by a return on equity (ROE) of 1.8253 and a return on assets (ROA) of 1.0271, both of which are strong indicators of efficient use of equity and assets. These metrics suggest that Take Solutions is generating solid returns for its shareholders and effectively utilizing its asset base. Take Solutions' revenue is not disclosed in the latest financial snapshot, but the company's global client base includes large and small biopharmaceutical and device companies, as well as U.S. federal agencies like the CDC and the DoD. This diverse client portfolio may help mitigate geographic and sector-specific risks. The company's growth trajectory is not clearly defined in the latest financial data, as revenue is reported as 0.0 INR. However, the positive net income of 374.67 million INR suggests that the company is profitable. The absence of capital expenditure and the presence of a small free cash flow indicate that the company may be in a maintenance phase rather than an expansion phase. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's strong equity position and lack of long-term debt contribute to its low liquidity risk. The dilution risk is also low, suggesting that the company is not expected to issue additional shares in the near term. Recent events and filings do not show any significant changes in the company's financial or operational status. The company's financial snapshot does not include any recent events or transcripts, but the absence of negative flags suggests that the company is operating within normal parameters.
Key takeaways
  • Take Solutions has a strong equity position with no long-term debt, contributing to low liquidity risk.
  • The company's ROE and ROA are strong, indicating efficient use of equity and assets.
  • The company's diverse client base, including U.S. federal agencies, may help mitigate geographic and sector-specific risks.
  • The positive net income suggests profitability, but the operating cash flow is negative, indicating potential liquidity concerns.
  • The company's low dilution risk suggests no immediate pressure to issue additional shares.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$0.00
Gross profit$0.00
Operating income-$74.7M
Net income$374.7M
R&D
SG&A
D&A
SBC
Operating cash flow-$164.5M
CapEx$0.00
Free cash flow$7.4M
Total assets$364.8M
Total liabilities$159.5M
Total equity$205.3M
Cash & equivalents$29.5M
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$205.3M
Net cash$29.5M
Current ratio1.5
Debt/Equity0.0
ROA1.0%
ROE1.8%
Cash conversion-44.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 254 companies
MetricTAKEActivity
Op margin7.0% medp25 3.8% · p75 10.2%
Net margin2.4% medp25 -0.6% · p75 5.4%
Gross margin50.1% medp25 23.6% · p75 72.3%
CapEx / revenue-6.8% medp25 -27.8% · p75 -1.7%
Debt / equity0.0%140.5% medp25 104.0% · p75 177.0%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 07:20 UTC#6c7f8803
Market quoteclose INR 38.54 · shares 0.15B diluted
no public URL
2026-05-05 19:27 UTC#2f7d643a
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 07:22 UTCJob: 5ba95ff3